Giardiasis Diagnosis and Treatment Practices Among Commercially Insured Persons in the United States | Zendy

Karlyn D. Beer | Zendy; Sarah A. Collier | Zendy; Fan Du | Zendy; Julia W. Gargano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Giardiasis Diagnosis and Treatment Practices Among Commercially Insured Persons in the United States

Author(s) -

Karlyn D. Beer,

Sarah A. Collier,

Fan Du,

Julia W. Gargano

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix138

Subject(s) - medicine , medical prescription , giardia , antiparasitic , giardia lamblia , pediatrics , antiparasitic agent , diagnosis code , antibiotics , cohort , environmental health , pathology , population , veterinary medicine , pharmacology , biology , microbiology and biotechnology

Giardiasis, the most common enteric parasitic infection in the United States, causes an estimated 1.2 million episodes of illness annually. Published clinical recommendations include readily available Giardia-specific diagnostic testing and antiparasitic drugs. We investigated sequences of giardiasis diagnostic and treatment events using MarketScan, a large health insurance claims database.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research